S.Africa's rand partially recovers, but risks remain

JOHANNESBURG, July 26 (Reuters) - South Africa's rand recovered from early losses on Monday, with concerns over rising COVID-19 infections setting a cautious tone in global markets ahead of the U.S. Federal Reserve's meeting this week.

At 1540 GMT, the rand ZAR= traded at 14.8000 against the dollar, up 0.35% from its previous close.

The currency fell last week after the South African Reserve Bank suggested on Thursday that interest rates would stay relatively low.

The dollar has in recent sessions benefited from safe-haven buying on fears a surge in infections of the fast-spreading Delta variant could derail the global recovery, pressuring riskier assets, such as the rand.

The dollar has also been supported by inflationary concerns and prospects of an earlier than expected U.S. rate hike.

Market participants are now waiting for the U.S. central bank's meeting on Tuesday and Wednesday. While no policy change is expected, investors will look for clues on when the Fed might start reining in its easy monetary policies.

"A more dovish tone ... would help significantly with market concerns over global growth on the global rising third wave," said Annabel Bishop, chief economist at Investec.

Shares on the Johannesburg Stock Exchange were largely unchanged from Friday's close.

The benchmark all-share index .JALSH closed down 0.02% at 68,051 points, while the blue-chip index of top 40 companies .JTOPI closed up 0.02% to 61,946 points.

Shares in Anglo American Platinum AMSJ.J and Impala Platinum IMPJ.J jumped by more than 5% as Impala Platinum posted a four-fold jump in half year profits.

The resources index .JRESI was up 3.68%, which helped offset a fall in industrials, led by a slump in the shares of Naspers Ltd NPNJn.J and subsidiary Prosus PRX.AS , which were down on increased scrutiny of tech companies in China.

Naspers, through Prosus, holds around a 30% stake in Chinese internet and gaming giant Tencent 0700.HK .

Bonds strengthened, with the yield on the benchmark government bond due in 2030 down 13 basis points at 8.83%.
Reporting by Olivia Kumwenda-Mtambo and Promit Mukherjee Editing by Tomasz Janowski and Mark Potter

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.